Epigenomics, Seeking Balance after Roche Jilting, Adds Lung Cancer Dx to Pipeline; Q1 Revenue Slide | GenomeWeb

Three months after Roche backed out of a deal to co-develop tissue-based tests, including a potential rival to Genomic Health's trailblazing Oncotype Dx, Epigenomics is looking for a new platform for diagnostics and is expanding its pipeline, the company said last week.

Specifically, Epigenomics has added a blood-based lung cancer screening test to its pipeline that it intends to develop alone for the time being, Oliver Schacht, Epigenomics CFO, told Pharmacogenomics Reporter in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.